Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of May 2022. The filing, dated May 10, 2022, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is headquartered in Geneva, Switzerland, and files annual reports on Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a standalone financial statement.
Material Changes
The filing does not contain comparative financial data or details regarding material changes versus prior periods. The content is limited to the notification of the press release issuance.
Guidance, Outlook, and Risks
Specific guidance, management commentary, risks, contingencies, or unusual items are not detailed within the body of this Form 6-K. These details are contained within the attached press release (Exhibit 99.1), which is incorporated by reference into the company's registration statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Verify the content of the press release dated May 10, 2022 (Exhibit 99.1), as the Form 6-K itself contains no operational or financial data.
- Confirm the incorporation of this press release into the active registration statements (Form F-3 No. 333-255089 and Form S-8 No. 333-255124).
- Note that the filing was signed by Tim Dyer, Chief Executive Officer, on May 10, 2022.